All Oncology News

Frontline treatment with nivolumab significantly extended OS and PFS compared with dacarbazine in patients with untreated BRAF wild-type advanced melanoma.

The PD-1 inhibitor pembrolizumab significantly improved PFS by over 43% compared with chemotherapy as a treatment for patients with metastatic melanoma who were refractory to ipilimumab.

The FDA has approved bevacizumab in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.

Frontline treatment with neratinib in combination with paclitaxel demonstrated similar ORR and PFS as the combination of trastuzumab and paclitaxel while lowering the incidence of CNS metastases in patients with locally recurrent or metastatic HER2-positive breast cancer.

ASCO members who need hands-on assistance in practice management, quality care assessment and improvement, and efficiency and business intelligence will be able to contact a soon to be established clinical affairs department at the organization.

A growing understanding of follicular lymphoma pathogenesis is resulting in new drug candidates and approaches to clinical treatment.

The Centers for Medicare & Medicaid Services (CMS) announced that the agency plans to cover lung cancer screening using low-dose computed tomography (LDCT) for certain former and current smokers, a decision that could affect an estimated 4 million people.

As new therapies enter the treatment landscape for metastatic disease, the role of the oncology nurse becomes even more critical in educating patients about what side effects to look out for and the importance of reporting any adverse events promptly.

Dendreon, the maker of the first FDA-approved immunotherapy for advanced prostate cancer, sipuleucel-T (Provenge), has filed for chapter 11 bankruptcy.

To help clinicians rethink and redesign their practices by moving from a model that is driven by quantity of care to one focused on patients' health outcomes, the Centers for Medicare & Medicaid Services (CMS) will earmark $840 million to improve health outcomes and reduce unnecessary hospitalization and other overutilization of services.

Access to radium-223 dichloride has been restored following a temporary suspension in production by its manufacturer Bayer HealthCare Pharmaceuticals to adjust its manufacturing process to meet certain quality standards that the company has in place.

In what was described as a very difficult decision, ODAC voted 5-2 against the accelerated approval of the HDAC inhibitor panobinostat in combination with bortezomib and dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.

The addition of the GM-CSF agent sargramostim to the CTLA-4 inhibitor ipilimumab (Yervoy) prolonged overall survival (OS) and lowered toxicity for patients with unresectable stage III or IV melanoma

The FDA has approved the combination of ramucirumab and paclitaxel as a treatment for patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

The combination of paclitaxel and the angiogenesis inhibitor trebananib did not demonstrate a statistically significant improvement in overall survival when compared with paclitaxel alone for patients with recurrent platinum-resistant ovarian cancer.

A novel first-in-class covalent KRAS inhibitor SML-8-73-1 has demonstrated promise in preclinical studies, prompting a 3-year research collaboration between the Dana-Farber Cancer Institute and Astellas Pharma Inc.

This past Friday, the Centers for Medicare and Medicaid Services (CMS) released nearly 3,000 pages of regulations finalizing 2015 payment rates for various providers and services in the Medicare program, including physicians.

A consensus has emerged among oncology practitioners that palliative care should not be seen as end-of-life care but is best deployed early to help patients and their caregivers manage symptoms throughout the cancer treatment trajectory.

Treatment with eribulin mesylate improved overall survival of patients with triple-negative and HER2-negative metastatic breast cancer compared with standard chemotherapies.

Internationally renowned cancer biologist Benjamin G. Neel, MD, PhD, an expert in the field of cell signal transduction, has been named Director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center – a National Cancer Institute-designated cancer center.

Researchers analyzed artwork, advertisements and leisure time activities to estimate historic changes in UV exposure

Researchers at NYU Langone Medical Center conclude new drug in development may offer first alternative to standard chemotherapy for T-Cell Acute Lymphoblastic Leukemia

Nearly two-thirds of patients diagnosed with colorectal cancer report experiencing financial burden during their treatment, according to a study from the University of Michigan.

Mutations known to be involved in hematologic malignancies were found in the blood cells of 2%-3% of individuals over age 40 and 5%-6% of those over age 70.

The FDA has granted a breakthrough therapy designation to pembrolizumab (Keytruda), an anti-PD-1 therapy, for the treatment of patients with non-small cell lung cancer (NSCLC) who are EGFR mutation- or ALK rearrangement-negative and whose disease has progressed on or following platinum-based chemotherapy.

Suresh S. Ramalingam, MD, discusses results from a phase II trial exploring the potential of veliparib as a treatment for patients with squamous cell NSCLC.

Even as more hospitals seek to acquire medical groups and physician practices, this consolidation leads to higher expenditures through greater use of hospital-based ambulatory services, according to a recent study from the University of California, Berkeley School of Public Health.

Janssen Research & Development, LLC, has submitted a supplemental New Drug Application for ibrutinib (Imbruvica) as treatment for patients with Waldenström's macroglobulinemia (WM).

Ibrutinib has been approved by the European Commission for the treatment of adult patients with relapsed or refractory MCL and adult patients with CLL.

The FDA has granted a fast track designation to TAS-102 (tipiracil hydrochloride) as a treatment for patients with refractory metastatic colorectal cancer (mCRC), according to an announcement by Taiho Oncology, the company developing the drug in the United States.